

ASX and Media release

17 May 2013

## **Clinical progress of VGX-100 Phase 1 trial in advanced cancer patients to be presented at ASCO 2013 Annual Meeting**

Circadian Technologies Limited (ASX: CIR, OTCQX:CKDXY), through its 100% owned subsidiary Ceres Oncology Pty Ltd, is pleased to announce that a clinical update for its anti-VEGF-C antibody, VGX-100, in patients with advanced solid tumors will be presented in the "Trials in Progress" Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics poster session at the American Society of Clinical Oncology (ASCO) Annual Meeting to be held May 31 - June 4, 2013 in Chicago, USA.

The Annual ASCO Meeting attracts more than 25,000 oncology professionals from around the world providing a forum for cutting-edge scientific and clinical presentations in cancer research.

Dr Gerald Falchook from MD Anderson, Texas, USA, who is a principal investigator on the study, will present an overview of the Phase 1 clinical trial design which includes dose escalation with VGX-100 alone and in combination with bevacizumab (Avastin®). In addition, an interim update on patient recruitment and progress will be presented.

The VGX-100 abstract presentation information is listed below:

Title: Phase I study of VGX-100, an anti-VEGF-C monoclonal antibody, with or without bevacizumab, in patients (pts) with advanced solid tumors.  
Abstract No: TPS2619  
Presenter: Gerald Falchook, M.D., (MD Anderson Cancer Center)  
Date / Time: Monday, June 3, 2013, 8:00-11:45AM (CT)

The abstract can be found on the ASCO 2013 Annual Meeting website at:  
[http://abstracts2.asco.org/AbstView\\_132\\_116847.html](http://abstracts2.asco.org/AbstView_132_116847.html)

### *Company enquiries*

Robert Klupacs  
CEO & Managing Director –  
Circadian  
Tel: +61 (0) 3 9826 0399 or  
[robert.klupacs@circadian.com.au](mailto:robert.klupacs@circadian.com.au)

### *Media enquiries – international*

Lauren Glaser  
The Trout Group LLC  
251 Post Street, Suite 412  
San Francisco, CA 94108  
Tel +1 215 740 8468  
[lglaser@troutgroup.com](mailto:lglaser@troutgroup.com)

## About Ceres Oncology Pty Ltd

Ceres Oncology Pty Ltd is a 100% owned subsidiary of Circadian Technologies Limited based in Melbourne, Australia. Ceres is developing VGX-100, which is a fully human monoclonal antibody that specifically and potently blocks the activity of vascular endothelial growth factor C (VEGF-C) which is involved in tumour angiogenesis (blood vessel growth), lymphangiogenesis (lymphatic vessel growth) and vascular leakage. By targeting and inhibiting the effects of VEGF-C, VGX-100 may have a broad utility in a range of oncology related disease states characterised by aberrant blood and/or lymphatic vessel growth, vascular leakage or edema, and/or inflammation, including solid tumours and lymphedema.

## About Circadian Technologies Limited

Circadian (ASX:CIR; OTCQX:CKDXY) is a biologics drug developer focusing on cancer, cancer related and ophthalmic disease therapies. It controls exclusive worldwide rights to a significant intellectual property portfolio around Vascular Endothelial Growth Factor (VEGF)-C and -D and VEGFR-3. The applications for the VEGF technology, which functions in regulating blood and lymphatic vessel growth, are substantial and broad. Circadian's internal product development programs are primarily focused on developing VGX-100 (a human antibody against VEGF-C) as a treatment for lymphedema resulting from breast cancer treatment and solid tumours, in particular glioblastoma and colorectal cancer through its subsidiary Ceres Oncology, as well as developing VGX-300 (soluble VEGFR-3) for 'back of the eye' disease such as "wet" Age Related Macular Degeneration through its subsidiary Opthea. Circadian has also licensed rights to some parts of its intellectual property portfolio for the development of other products to ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, including the anti-lymphatic antibody-based drug IMC-3C5 targeting VEGFR-3.

---

## Inherent risks of Investment in Biotechnology Companies

There are a number of inherent risks associated with the development of pharmaceutical products to a marketable stage. The lengthy clinical trial process is designed to assess the safety and efficacy of a drug prior to commercialisation and a significant proportion of drugs fail one or both of these criteria. Other risks include uncertainty of patent protection and proprietary rights, whether patent applications and issued patents will offer adequate protection to enable product development, the obtaining of necessary drug regulatory authority approvals and difficulties caused by the rapid advancements in technology. Companies such as Circadian are dependent on the success of their research and development projects and on the ability to attract funding to support these activities. Investment in research and development projects cannot be assessed on the same fundamentals as trading and manufacturing enterprises. Thus investment in companies specialising in drug development must be regarded as highly speculative. Circadian strongly recommends that professional investment advice be sought prior to such investments.

## Forward-looking statements

Certain statements in this ASX announcement may contain forward-looking statements regarding Company business and the therapeutic and commercial potential of its technologies and products in development. Any statement describing Company goals, expectations, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the process of discovering, developing and commercialising drugs that can be proven to be safe and effective for use as human therapeutics, and in the endeavour of building a business around such products and services. Circadian undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Actual results could differ materially from those discussed in this ASX announcement.